{"id":"https://openalex.org/W1845065486","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.10506","title":"A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report.","display_name":"A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report.","publication_year":2014,"publication_date":"2014-05-20","ids":{"openalex":"https://openalex.org/W1845065486","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.10506","mag":"1845065486"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2014.32.15_suppl.10506","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.10506","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.10506","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091057405","display_name":"Michael Charles Heinrich","orcid":"https://orcid.org/0000-0003-3790-0478","observed_orcids":["https://orcid.org/0000-0003-3790-0478"]},"institutions":[{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]},{"id":"https://openalex.org/I2803065977","display_name":"Portland VA Medical Center","ror":"https://ror.org/02v3txv81","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2803065977","https://openalex.org/I4210144745"]},{"id":"https://openalex.org/I4390039369","display_name":"OHSU Knight Cancer Institute","ror":"https://ror.org/002shna07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael C. Heinrich","raw_affiliation_strings":["OHSU Knight Cancer Institute and Portland VA Medical Center, Portland, OR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OHSU Knight Cancer Institute and Portland VA Medical Center, Portland, OR","institution_ids":["https://openalex.org/I165690674","https://openalex.org/I2803065977","https://openalex.org/I4390039369"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085336500","display_name":"Margaret von Mehren","orcid":"https://orcid.org/0000-0001-6158-890X","observed_orcids":["https://orcid.org/0000-0001-6158-890X"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Margaret vonMehren","raw_affiliation_strings":["Fox Chase Cancer Center, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fox Chase Cancer Center, Philadelphia, PA","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060580923","display_name":"George D. Demetri","orcid":"https://orcid.org/0000-0002-0045-4809","observed_orcids":["https://orcid.org/0000-0002-0045-4809"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George D. Demetri","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040359760","display_name":"Jonathan Alfred Fletcher","orcid":"https://orcid.org/0000-0002-5109-2588","observed_orcids":["https://orcid.org/0000-0002-5109-2588"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan A. Fletcher","raw_affiliation_strings":["Brigham and Women's Hospital/Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brigham and Women's Hospital/Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113277503","display_name":"Jichao G Sun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jichao Sun","raw_affiliation_strings":["Ariad Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ariad Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030244109","display_name":"John Hodgson","orcid":"https://orcid.org/0000-0003-3021-802X","observed_orcids":["https://orcid.org/0000-0003-3021-802X"]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Graeme Hodgson","raw_affiliation_strings":["Ariad Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ariad Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035320303","display_name":"Victor M. Rivera","orcid":"https://orcid.org/0000-0002-7258-3001","observed_orcids":["https://orcid.org/0000-0002-7258-3001"]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Victor M. Rivera","raw_affiliation_strings":["ARIAD Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ARIAD Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107168404","display_name":"Christopher D. Turner","orcid":"https://orcid.org/0000-0003-2348-5373","observed_orcids":["https://orcid.org/0000-0003-2348-5373"]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher D. Turner","raw_affiliation_strings":["ARIAD Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ARIAD Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078289621","display_name":"Suzanne George","orcid":"https://orcid.org/0000-0002-1284-8493","observed_orcids":["https://orcid.org/0000-0002-1284-8493","https://orcid.org/0000-0002-8777-8530"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Suzanne George","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":28,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"32","issue":"15_suppl","first_page":"10506","last_page":"10506"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11485","display_name":"Gastrointestinal Tumor Research and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11485","display_name":"Gastrointestinal Tumor Research and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11346","display_name":"Mast cells and histamine","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ponatinib","display_name":"ponatinib","score":0.9950000047683716},{"id":"https://openalex.org/keywords/gastrointestinal-stromal-tumor","display_name":"gastrointestinal stromal tumor","score":0.9710000157356262},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitor-resistance","display_name":"tyrosine kinase inhibitor resistance","score":0.9390000104904175},{"id":"https://openalex.org/keywords/kit-exon-11-mutation","display_name":"KIT exon 11 mutation","score":0.9079999923706055},{"id":"https://openalex.org/keywords/pdgfra","display_name":"PDGFRA","score":0.8100000023841858},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.6909999847412109},{"id":"https://openalex.org/keywords/clinical-benefit-rate","display_name":"clinical benefit rate","score":0.824999988079071},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.8270000219345093},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.5220000147819519},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.33399999141693115},{"id":"https://openalex.org/keywords/oral-tyrosine-kinase-inhibitor","display_name":"oral tyrosine kinase inhibitor","score":0.7149999737739563},{"id":"https://openalex.org/keywords/fdg-pet-response","display_name":"FDG-PET response","score":0.628000020980835},{"id":"https://openalex.org/keywords/recist-1-1","display_name":"RECIST 1.1","score":0.5989999771118164}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9289340972900391},{"id":"https://openalex.org/C2780381907","wikidata":"https://www.wikidata.org/wiki/Q198728","display_name":"Ponatinib","level":5,"score":0.8671952486038208},{"id":"https://openalex.org/C2775922572","wikidata":"https://www.wikidata.org/wiki/Q83567","display_name":"GiST","level":3,"score":0.7124066948890686},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6625357270240784},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6561542749404907},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6200088858604431},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5428739190101624},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47909215092658997},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.4128877520561218},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4002513289451599},{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.3952144384384155},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3600340783596039},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3426181674003601},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.2905651330947876},{"id":"https://openalex.org/C16930146","wikidata":"https://www.wikidata.org/wiki/Q4381253","display_name":"Stromal cell","level":2,"score":0.1139996349811554},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.06966397166252136}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2014.32.15_suppl.10506","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.10506","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.10506","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2473386911","https://openalex.org/W2278555352","https://openalex.org/W4210380403","https://openalex.org/W2889990731","https://openalex.org/W4412720622","https://openalex.org/W3030826315","https://openalex.org/W2612255169","https://openalex.org/W2109791697","https://openalex.org/W2600034638","https://openalex.org/W2323173556"],"abstract_inverted_index":{"10506":[0],"Background:":[1],"Ponatinib":[2],"is":[3,125],"an":[4],"oral":[5],"TKI":[6,51,75,361],"that":[7,348],"has":[8,350],"potent":[9],"preclinical":[10,27],"activity":[11,28,351],"against":[12,29],"several":[13],"mutant":[14],"isoforms":[15],"of":[16,33,64,88,122,147,162,191,216,290,343,359],"KIT,":[17],"including":[18],"secondary":[19],"exon":[20,93],"17":[21,206],"resistance":[22,35],"mutants,":[23],"and":[24,62,241,268],"PDGFRA.":[25],"Its":[26],"a":[30,163],"broad":[31],"spectrum":[32],"clinically-relevant":[34],"mutations":[36,90],"suggests":[37,347],"it":[38],"may":[39],"provide":[40],"clinical":[41,98],"benefit":[42,99],"in":[43,70,91,108,116,132,171,265,315,352],"pts":[44,73,124,144,166,192,207,253,317,353],"with":[45,145,254,272,354],"GIST":[46,72,356],"resistant":[47],"to":[48,129,141,158],"standard":[49],"approved":[50,151,183,188],"therapies.":[52],"Methods:":[53],"This":[54],"phase":[55],"2":[56,181],"single":[57],"arm":[58],"trial":[59,346,364],"evaluates":[60],"efficacy":[61],"safety":[63,130],"ponatinib":[65,134,349],"at":[66,233],"45":[67,165],"mg":[68],"QD":[69],"advanced":[71,355],"after":[74,357],"failure.":[76],"Cohorts":[77],"are":[78,138],"enrolled":[79,169],"based":[80],"on":[81,126,270],"the":[82],"presence":[83],"(A)":[84],"or":[85,274],"absence":[86],"(B)":[87],"primary":[89],"KIT":[92],"11.":[94],"Primary":[95],"end":[96,112],"point:":[97],"rate":[100],"(CBR=CR+PR+SD":[101],"\u226516":[102,234],"wks)":[103],"by":[104],"modified":[105],"RECIST":[106],"1.1":[107],"Cohort":[109,117,172,222,226,230,244,251,276,281],"A.":[110],"Secondary":[111],"points":[113],"include":[114,142],"CBR":[115,232],"B,":[118],"ORR,":[119],"safety/tolerability.":[120],"Enrollment":[121],"new":[123],"hold":[127],"due":[128],"observations":[131],"other":[133],"trials;":[135],"enrollment":[136],"criteria":[137],"being":[139],"revised":[140],"only":[143],"failure":[146,358],"all":[148],"3":[149,186,228],"TKIs":[150],"for":[152],"GIST.":[153],"NCT01874665.":[154,366],"Results:":[155],"From":[156],"June":[157],"Oct":[159],"2013,":[160],"35":[161],"planned":[164],"have":[167],"been":[168],"(24":[170],"A).":[173],"Baseline":[174],"characteristics:":[175],"median":[176,199,220],"age":[177],"58":[178],"yrs;":[179],"46%":[180,185],"prior":[182,187,195,360],"TKIs,":[184],"TKIs.":[189],"74%":[190],"had":[193,261,330],"\u22654":[194],"cancer":[196],"regimens.":[197],"The":[198],"time":[200],"since":[201],"diagnosis":[202],"was":[203,334],"6":[204,217],"yrs.":[205],"discontinued":[208],"(8":[209],"PD,":[210],"5":[211,250],"AE,":[212],"4":[213,224],"other).":[214],"As":[215],"Jan":[218],"2014,":[219],"follow-up:":[221],"A":[223,231,245,252],"mos,":[225],"B":[227,277,282],"mos.":[229],"wks:":[235],"55%":[236],"(11/20":[237],"pts)":[238],"1":[239,335],"PR":[240],"10":[242],"SD.":[243],"ORR:":[246,283],"8%":[247],"(2/24).":[248],"All":[249],"matched":[255],"PET":[256],"scans":[257],"(BL":[258],"v.":[259],"C1)":[260],"decreased":[262],"FDG":[263],"uptake":[264],"active":[266],"lesions":[267],"remain":[269],"study":[271],"SD":[273],"better.":[275],"CBR:":[278],"22%":[279],"(2/9);":[280],"0%.":[284],"Most":[285],"common":[286],"(\u226530%)":[287],"treatment-emergent":[288],"AEs":[289,312],"any":[291],"grade":[292],"are:":[293,318],"rash":[294],"(54%),":[295],"fatigue":[296,326],"(46%),":[297,299],"myalgia":[298],"dry":[300],"skin":[301],"(40%),":[302,304],"headache":[303],"abdominal":[305,319],"pain":[306,320],"(34%),":[307],"constipation":[308],"(34%).":[309],"Treatment-emergent":[310],"serious":[311],"(SAEs)":[313],"occurring":[314],"\u22652":[316],"(11%),":[321],"nausea":[322],"(6%),":[323,325],"vomiting":[324],"(6%).":[327],"One":[328],"pt":[329],"myocardial":[331],"ischemia.":[332],"There":[333],"death":[336],"(pneumonia)":[337],"possibly":[338],"ponatinib-related.":[339],"Conclusions:":[340],"Initial":[341],"analysis":[342],"this":[344],"ongoing":[345],"therapy.":[362],"Clinical":[363],"information:":[365]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}